AstraZeneca, through its Access 360 and AZ&Me programs, offers a range of patient assistance to help streamline access and reimbursement for select AstraZeneca medicines. A complete list of AstraZeneca oncology products and their related assistance programs is provided in the Table.
AstraZeneca Access 360
Access 360 can assist you and your patients with benefits investigation, prior authorization support, pharmacy research and coordination, follow-up support, claims and appeal process support, and affordability options. AstraZeneca Field Reimbursement Managers are available to assist with providing access and reimbursement support by calling 844-275-2360. There are no eligibility criteria to receive Access 360 support; any patient or provider can call 844-275-2360 to request support. To enroll in the Access 360 program, visit MyAccess360.com and select the appropriate medication from the drop-down menu.
Co-pay Savings Program
AstraZeneca offers a Co-pay Savings Program to help eligible, commercially insured patients with out-of-pocket costs. Patients may be eligible if they:
Have been prescribed Calquence, Faslodex, Imfinzi, Iressa, Lynparza, or Tagrisso
Are covered by commercial insurance and their insurance does not cover the full cost of their prescription
Are a resident of the United States or Puerto Rico
Do not participate in any state- or federal-funded programs, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense, or TRICARE.
To enroll in the Co-pay Savings Program, visit MyAccess360.com and select the appropriate medication from the drop-down menu.
AZ&Me Prescription Savings Program
The AZ&Me Prescription Savings Program is designed to help qualifying patients without insurance and, in some cases, people with Medicare. Patients may be eligible if they:
Are a resident of the United States
Are not currently receiving prescription drug coverage under a private insurance or government program (excluding Medicare), or receiving any other assistance to help pay for medicine
Meet certain financial criteria.
If your patient is a Medicare beneficiary, to enroll in the AZ&Me Prescription Savings Program they must not be eligible for or enrolled in Low Income Subsidy (LIS) for Medicare Part D.
If your patient has experienced a life-changing event in the past year, such as loss of employment or change of income, and their financial documentation does not accurately reflect their current situation, they are encouraged to apply for the AZ&Me Prescription Savings Program. They may still meet the criteria to enroll.
To enroll your patient in the AZ&Me Prescription Savings Program, visit AZandMeApp.com.
TABLE AstraZeneca Oncology Drugs
Drugs
Indications
Patient support programs
Drug
Calquence (acalabrutinib)
Indications
Treatment of mantle-cell lymphoma after ≥1 previous therapies; treatment of adults with chronic lymphocytic leukemia or with small lymphocytic lymphoma
Treatment of adult patients with unresectable stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy; in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small-cell lung cancer
Adjuvant treatment after tumor resection in adult patients with NSCLC and EGFR exon 19 deletions or exon 21 L858R mutations; first-line treatment of adult patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test; treatment of NSCLC with EGFR T790 mutation, as determined by an FDA-approved test
Treatment of HR-positive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy; HR-positive advanced breast cancer in postmenopausal women whose disease progressed after endocrine therapy; in combination with palbociclib or abemaciclib, for HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy; HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine-based therapy or following disease progression on endocrine therapy
Lynparza (olaparib) Indications
In select patients as determined by an FDA-approved diagnostic for Lynparza, maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability; maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; in select patients as determined by an FDA-approved diagnostic for Lynparza, treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide or abiraterone
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
